From: Therapeutic advancement of chronic lymphocytic leukemia
Reference (year) | Regimen | Phase | Number of patients | Treatment status | CR,% | ORR,% | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|---|
Woyach, 2011 [17] | FR (C) | 2 | 51 | Untreated | 47 | 90 | 42 | 85 |
 | FR (S) |  | 53 | Untreated | 28 | 77 |  |  |
Kay, 2007 [18] | PCR | 2 | 64 | Untreated | 41 | 91 | 32.6 | Not Rep |
Kay, 2010 [19] | PR | 2 | 33 | Untreated | 27 | 76 | 12 | Not Rep |
Reynolds, 2011 [20] | PCR | 3 | 92 | 20% Pretreated | 7 | 49 | NR | NR |
 | FCR |  | 92 | 20% Pretreated | 14 | 59 | NR | NR |
Wierda, 2011 [21] | FBR | 1/2 | 14 | Untreated | 36 | 93 | Not Rep | Not Rep |
Bosch, 2011 [23] | R-FCM | 2 | 72 | Untreated | 82 | 93 | Not Rep | Not Rep |
Jenke, 2011 [24] | CHOP-R | 2 | 26 | Pretreated, F-ref | 0 | 54 | 11 | 27 |
 |  |  | 15 | Pretreated, RT | 7 | 67 | 15 | 27 |
 |  |  | 15 | Pretreated, AIC | 0 | 82 | 14 | 50 |